Starting this July 1, Medicare begins the pilot program called Medicare GLP-1 Bridge, offering coverage for weight loss medications to millions of beneficiaries for the first time in history.

This program will be launched as part of an agreement between the Trump administration and drug makers Eli Lilly and Novo Nordisk, and seeks to address the growing problem of obesity among older adults.

It is worth noting that the law prohibits Medicare from covering weight loss medications, but the Centers for Medicare and Medicaid Services (CMS) is authorized to conduct short-term pilot projects to test new payment and coverage models, CNN points out.

Illustrative personal cases

Washington resident Mary Abrahamson, who is one of the beneficiaries anticipating this significant change, shared her experience. At 71 years old, he has faced limitations due to his weight, but with the reduction in costs of medications such as Zepbound, he hopes to be able to access a treatment that will allow him to improve his quality of life.

“With this weight loss, I feel ten years younger,” said Abrahamson, who no longer suffers from sleep apnea or other ailments since she started taking the customized GLP-1.

"It has changed my life for the better. I don't want to leave it," CNN reported his statements.

Similarly, other recipients, such as Deb Cooperman and Diane Lane-Cormier, share experiences of uncertainty and frustration regarding their eligibility.

Economic impact on beneficiaries

With a $50 monthly copay for medications, many beneficiaries will see a significant reduction in their expenses, allowing them to attend to other essential needs.

However, there are still concerns about affordability and permanence of coverage after the pilot program concludes in 2028.

Eligibility criteria

Beneficiaries must meet specific health criteria and be enrolled in a Medicare Part D drug coverage plan. However, enrollees are not eligible if they already receive GLP-1 medications through their Medicare Part D drug plan or if they have type 2 diabetes, moderate to severe sleep apnea, or fatty liver disease.

Criteria include having a body mass index (BMI) of 35 or higher, or a BMI of 30-35 along with pre-existing health conditions.

If they meet the requirements, they must ask their doctors to send a prescription to the pharmacy and then complete a prior authorization form.

Program Outlook

Health experts anticipate high demand from eligible beneficiaries to join the program. However, uncertainty remains about how many will actually enroll and what the total cost to Medicare will be.

The administration hopes that the program will result in long-term savings by improving the health of beneficiaries and reducing cardiovascular risks. As the program progresses, the possibility of implementing a more permanent coverage model will be evaluated.